

Research To Practice | Oncology Videos
Dr Neil Love
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.
Episodes
Mentioned books

Nov 21, 2026 • 55min
GPRC5D-Directed Therapies for Multiple Myeloma — An Interview with Prof Rakesh Popat
Featuring an interview with Prof Rakesh Popat, including the following topics: Overview of GPRC5D and its clinical significance (0:00) Key findings from Phase II TALisman study regarding dysgeusia assessment for patients receiving talquetamab (2:30) Mitigating dysgeusia and dry mouth arising from GPRC5D-directed therapy (6:25) Key findings from the Phase III MonumenTAL-3 study (11:49) Selection factors for GPRC5D- and BCMA-directed therapies (15:16) Managing extramedullary multiple myeloma (MM) with GPRC5D-targeted therapies and beyond (18:30) Key findings with arlocabtagene autoleucel (arlo-cel) for relapsed/refractory (R/R) MM (20:47) Ramantamig and other GPRC5D-targeted approaches (25:32) Comparing arlo-cel to ciltacabtagene autoleucel for MM; CNS issues with GPRC5D-directed therapies (28:42) Case: A man in his late 70s with a history of chronic obstructive pulmonary disease and t(4;14) R/R MM who receives fourth-line talquetamab and attains a very good partial response (38:27) Cases: A man in his late 40s with t(11;14), del(17p) R/R MM who enrolls in the Phase II QUINTESSENTIAL-2 study for third-line treatment; a man in his late 60s with t(11;14), del(17p) MM and early relapse after third-line autologous stem cell transplant (45:18) Guidance on sequencing BCMA- and GPRC5D-directed therapies (47:35) Importance of tumor debulking; access to arlo-cel (52:27) CME information and select publications

Nov 20, 2026 • 19min
GPRC5D-Directed Therapies for Multiple Myeloma — An Interview with Prof Rakesh Popat (Companion Faculty Lecture)
Featuring a slide presentation and related discussion from Prof Rakesh Popat, including the following topics: Overview of GPRC5D in multiple myeloma (0:00) Key findings from the Phase I/II MonumenTAL-1 clinical trial (2:01) Key findings from the Phase III MonumenTAL-3 trial (5:50) Key findings from a Phase I study of arlocabtagene autoleucel and Phase II QUINTESSENTIAL study; ongoing Phase III QUINTESSENTIAL-3 study (8:51) Key findings from the Phase Ib/II RedirecTT-1 and Phase III MonumenTAL-6 study (13:29) Other GPRC5D treatments in development (16:44) CME information and select publications

Nov 16, 2026 • 16min
Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 3: An Interview with Dr Matthew Lunning on The Utility of Tafasitamab
Featuring an interview with Dr Matthew Lunning, including the following topics: Tafasitamab for follicular lymphoma (0:00) frontMIND Phase III trial of tafasitamab/lenalidomide/R-CHOP for diffuse large B-cell lymphoma (7:51) CME information and select publications

Nov 14, 2026 • 58min
Follicular Lymphoma — Where We Are, Where We're Headed in the Use of Bispecific Antibodies
Matthew Matasar, a lymphoma specialist at Rutgers, and Chan Chea, a hematologist and clinical investigator in Perth, explore bispecific antibodies in follicular lymphoma. They discuss mechanisms, second-line treatment choices, sequencing with CAR-T, and real-world complications including cytokine release syndrome and infections. The conversation also spotlights surovatamig, first-line trials, multispecific antibodies, and emerging treatment targets.

Nov 13, 2026 • 27min
Follicular Lymphoma | Matthew Matasar, MD
Where We Are, Where We're Headed: Bispecific Antibodies in the Management of Follicular Lymphoma | Faculty Presentation 2: Emerging Bispecific Antibody Strategies for Follicular Lymphoma — Dr Matasar CME information and select publications

Nov 13, 2026 • 27min
Follicular Lymphoma | Professor Chan Cheah, MBBS (Hons), DMSc
Where We Are, Where We're Headed: Bispecific Antibodies in the Management of Follicular Lymphoma | Faculty Presentation 1: Current Use of Bispecific Antibodies for Relapsed/Refractory Follicular Lymphoma — Prof Cheah CME information and select publications

Nov 11, 2026 • 1h 2min
Relapsed/Refractory Multiple Myeloma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Featuring perspectives from Dr Sagar Lonial and Dr Paul G Richardson, including the following topics: Multiple Myeloma (0:00) Introduction: ESMO 2026; Recent FDA Approvals (1:53) Chimeric Antigen Receptor T-Cell Therapy — Dr Lonial (2:46) Bispecific Antibodies — Dr Lonial (19:16) Antibody-Drug Conjugates — Dr Richardson (37:08) Up-Front Treatment; Cereblon E3 Ligase Modulators — Dr Richardson (50:10) CME information and select publications

Nov 10, 2026 • 59min
Prostate Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Featuring perspectives from Dr Neeraj Agarwal and Dr Emmanuel S Antonarakis, including the following topics: Introduction: ESMO 2026; Recent FDA Approvals (0:00) Selection of Endocrine Therapy — Dr Antonarakis (2:24) Utility of PARP Inhibitors — Dr Agarwal (22:59) AKT Inhibition for PTEN-Deficient Disease — Dr Antonarakis (35:42) Radiopharmaceuticals — Dr Agarwal (45:02) CME information and select publications

Nov 9, 2026 • 2h 22min
Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Featuring perspectives from Dr Charles E Geyer Jr, Dr Maryam Lustberg, Dr Rita Nanda and Dr Seth Wander, including the following topics: Breast Cancer Introduction: ESMO 2026; Recent FDA Approvals (0:00) ER-Positive Breast Cancer (5:01) HER2-Positive Breast Cancer (1:19:08) Triple-Negative Breast Cancer (1:48:54) CME information and select publications

Nov 6, 2026 • 18min
Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 2: An Interview with Dr Matthew Lunning on Novel Combination Regimens
Featuring an interview with Dr Matthew Lunning, including the following topics: Bispecific antibody/antibody-drug conjugate combinations (0:00) A man in his late 90s with mantle cell lymphoma — Ann LaCasce, MD, MMSc (8:07) CME information and select publications


